title: Non-dopaminergic treatments for motor control in Parkinson's disease.
abstract: The pathological processes underlying Parkinson's disease (PD) involve more than dopamine cell loss within the midbrain. These non-dopaminergic neurotransmitters include noradrenergic, serotonergic, glutamatergic, and cholinergic systems within cortical, brainstem and basal ganglia regions. Several non-dopaminergic treatments are now in clinical use to treat motor symptoms of PD, or are being evaluated as potential therapies. Agents for symptomatic monotherapy and as adjunct to dopaminergic therapies for motor symptoms include adenosine A2A antagonists and the mixed monoamine-B inhibitor (MAO-BI) and glutamate release agent safinamide. The largest area of potential use for non-dopaminergic drugs is as add-on therapy for motor fluctuations. Thus adenosine A2A antagonists, safinamide, and the antiepileptic agent zonisamide can extend the duration of action of levodopa. To reduce levodopa-induced dyskinesia, drugs that target overactive glutamatergic neurotransmission can be used, and include the non-selective N-methyl D-aspartate antagonist amantadine. More recently, selective metabotropic glutamate receptor (mGluR₅) antagonists are being evaluated in phase II randomized controlled trials. Serotonergic agents acting as 5-HT2A/2C antagonists, such as the atypical antipsychotic clozapine, may also reduce dyskinesia. 5-HT1A agonists theoretically can reduce dyskinesia, but in practice, may also worsen PD motor symptoms, and so clinical applicability has not yet been shown. Noradrenergic α2A antagonism using fipamezole can potentially reduce dyskinesia. Several non-dopaminergic agents have also been investigated to reduce non-levodopa-responsive motor symptoms such as gait and tremor. Thus the cholinesterase inhibitor donepezil showed mild benefit in gait, while the predominantly noradrenergic re-uptake inhibitor methylphenidate had conflicting results in advanced PD subjects. Tremor in PD may respond to muscarinic M4 cholinergic antagonists (anticholinergics), but tolerability is often poor. Alternatives include β-adrenergic antagonists such as propranolol. Other options include 5-HT2A antagonists, and drugs that have mixed binding properties involving serotonin and acetylcholine, such as clozapine and the antidepressant mirtazapine, can be effective in reducing PD tremor. Many other non-dopaminergic agents are in preclinical and phase I/II early stages of study, and the reader is directed to recent reviews. While levodopa remains the most effective agent to treat motor symptoms in PD, the overall approach to using non-dopaminergic drugs in PD is to reduce reliance on levodopa and to target non-levodopa-responsive symptoms.
authors.affiliation: Movement Disorders Clinic, Division of Neurology, University of Toronto, Toronto Western Hospital, 399 Bathurst Street MCL7-412, Toronto, ON, M5T 2S8, Canada, sfox@uhnresearch.ca.
authors.forename: Susan H
authors.initials: SH
authors.lastname: Fox
mesh_terms: D058917:Adenosine A2 Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects; D004351:Drug Resistance; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D020233:Gait Disorders, Neurologic / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008636:Mesencephalon / Q000187:drug effects / Q000378:metabolism; D058990:Molecular Targeted Therapy; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D056687:Off-Label Use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D014202:Tremor / Q000209:etiology / Q000517:prevention & control*
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D000978:Antiparkinson Agents; D015259:Dopamine Agents; D008996:Monoamine Oxidase Inhibitors; D012702:Serotonin Antagonists; D007980:Levodopa
references.citation: Pharmacol Rev. 2013 Jan 10;65(1):171-222
references.pmid: 23319549
references.citation: Neurology. 1997 Dec;49(6):1587-90
references.pmid: 9409351
references.citation: Mov Disord. 2011 Jun;26(7):1243-50
references.pmid: 21484867
references.citation: Lancet Neurol. 2012 Jul;11(7):589-96
references.pmid: 22658702
references.citation: Neurology. 2013 May 14;80(20):1850-5
references.pmid: 23596065
references.citation: J Neural Transm (Vienna). 1998;105(10-12):1213-28
references.pmid: 9928890
references.citation: Neurology. 2007 Jan 2;68(1):45-50
references.pmid: 17200492
references.citation: Brain Res. 1990 Feb 26;510(1):104-7
references.pmid: 1691042
references.citation: Mov Disord. 2007 Jan 15;22(2):179-86
references.pmid: 17094088
references.citation: Brain. 2007 Jul;130(Pt 7):1819-33
references.pmid: 17452372
references.citation: Mov Disord. 2006 Oct;21(10):1578-94
references.pmid: 16874752
references.citation: Lancet Neurol. 2011 Mar;10(3):221-9
references.pmid: 21315654
references.citation: J Neurosci. 2000 Oct 15;20(20):7782-9
references.pmid: 11027242
references.citation: J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):295-7
references.pmid: 14742609
references.citation: Ann Neurol. 1998 Apr;43(4):507-13
references.pmid: 9546333
references.citation: Am J Psychiatry. 2001 Mar;158(3):360-9
references.pmid: 11229973
references.citation: J Neural Transm Park Dis Dement Sect. 1993;5(1):27-34
references.pmid: 8439390
references.citation: Mov Disord. 2003 Oct;18 Suppl 7:S43-51
references.pmid: 14531046
references.citation: Mov Disord. 2010 Jul 30;25(10):1437-43
references.pmid: 20629136
references.citation: Trends Neurosci. 1990 Jul;13(7):281-5
references.pmid: 1695404
references.citation: Brain. 2008 Dec;131(Pt 12):3380-94
references.pmid: 18952677
references.citation: J Neuropathol Exp Neurol. 1991 Nov;50(6):743-55
references.pmid: 1748881
references.citation: Cochrane Database Syst Rev. 2003;(1):CD003361
references.pmid: 12535472
references.citation: J Clin Invest. 2010 Aug;120(8):2745-54
references.pmid: 20628197
references.citation: Neurology. 2008 Jun 3;70(23):2233-40
references.pmid: 18519872
references.citation: Mov Disord. 2012 Jan;27(1):106-12
references.pmid: 21913224
references.citation: Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
references.pmid: 12498954
references.citation: Neurology. 2003 Aug 12;61(3):297-303
references.pmid: 12913187
references.citation: Mov Disord. 2013 Jul;28(8):1138-41
references.pmid: 23483627
references.citation: Neurology. 2003 Aug 12;61(3):293-6
references.pmid: 12913186
references.citation: Ann Neurol. 2008 Mar;63(3):295-302
references.pmid: 18306243
references.citation: CNS Drugs. 2012 Dec;26(12):1017-32
references.pmid: 23114872
references.citation: Eur J Pharmacol. 2004 Feb 6;485(1-3):159-64
references.pmid: 14757136
references.citation: Mov Disord. 2011 Oct;26 Suppl 3:S2-41
references.pmid: 22021173
references.citation: Neurology. 2009 Nov 17;73(20):1670-6
references.pmid: 19917989
references.citation: Parkinsonism Relat Disord. 2012 May;18(4):370-6
references.pmid: 22316635
references.citation: Ann Neurol. 2004 Jun;55(6):761-5
references.pmid: 15174009
references.citation: Neuroscience. 1991;41(2-3):507-23
references.pmid: 1870701
references.citation: Med Hypotheses. 2013 Feb;80(2):209-12
references.pmid: 23265352
references.citation: Mov Disord. 2008 Apr 15;23(5):700-7
references.pmid: 18175337
references.citation: Mov Disord. 2005 Aug;20(8):919-31
references.pmid: 16007614
references.citation: J Neural Transm (Vienna). 2011 Dec;118(12):1661-90
references.pmid: 21881839
references.citation: Mov Disord. 2010 Jul 30;25(10):1357-63
references.pmid: 20198649
references.citation: Neurology. 1997 Apr;48(4):1077-81
references.pmid: 9109903
references.citation: Mov Disord. 2003 Sep;18(9):977-84
references.pmid: 14502664
references.citation: Mov Disord. 1998 May;13(3):377-82
references.pmid: 9613725
references.citation: Front Syst Neurosci. 2011 Jul 04;5:49
references.pmid: 21772815
references.citation: Psychopharmacology (Berl). 2003 Jan;165(3):229-37
references.pmid: 12420151
references.citation: Mov Disord. 2002 Jul;17(4):782-8
references.pmid: 12210876
references.citation: Neurology. 2003 Feb 25;60(4):601-5
references.pmid: 12601099
references.citation: Ann Neurol. 2000 Apr;47(4 Suppl 1):S60-8; discussion S68-9
references.pmid: 10762133
references.citation: Parkinsonism Relat Disord. 2014 Sep;20(9):947-56
references.pmid: 24951359
references.citation: Mov Disord. 2012 Feb;27(2):284-8
references.pmid: 22161845
references.citation: J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):376-7
references.pmid: 2056334
references.citation: Ann Neurol. 1990 Apr;27(4):373-85
references.pmid: 1972319
references.citation: J Neural Transm (Vienna). 2010 Nov;117(11):1279-86
references.pmid: 20803300
references.citation: Parkinsonism Relat Disord. 2002 Dec;9(2):125-6
references.pmid: 12473405
references.citation: Mov Disord. 2003 Nov;18(11):1301-5
references.pmid: 14639671
references.citation: Lancet Neurol. 2008 Oct;7(10):927-38
references.pmid: 18848312
references.citation: Neurology. 2004 Feb 10;62(3):381-8
references.pmid: 14872017
references.citation: J Pharmacol Exp Ther. 2004 Jul;310(1):386-94
references.pmid: 15004218
references.citation: Mov Disord. 2008 Nov 15;23(15):2177-85
references.pmid: 18831530
references.citation: Curr Opin Investig Drugs. 2004 Jul;5(7):720-6
references.pmid: 15298067
references.citation: Arch Neurol. 2001 Oct;58(10):1660-8
references.pmid: 11594926
references.citation: Clin Neuropharmacol. 2006 May-Jun;29(3):148-53
references.pmid: 16772814
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):1327-35
references.pmid: 16980569
references.citation: Mov Disord. 2005 Sep;20(9):1205-9
references.pmid: 15954135
references.citation: Physiol Behav. 2002 Dec;77(4-5):469-75
references.pmid: 12526985
references.citation: J Neurosci. 2001 Jan 15;21(2):RC121
references.pmid: 11160455
references.citation: Nat Rev Neurosci. 2005 Oct;6(10):787-98
references.pmid: 16276355
references.citation: Mov Disord. 2011 Feb 1;26(2):264-70
references.pmid: 21412833
references.citation: Parkinsonism Relat Disord. 2010 Jan;16(1):16-20
references.pmid: 19616987
references.citation: Clin Neuropharmacol. 1993 Oct;16(5):418-27
references.pmid: 8106150
references.citation: Mov Disord. 2008 Apr 30;23(6):837-44
references.pmid: 18307261
references.citation: Brain. 2008 Jan;131(Pt 1):120-31
references.pmid: 17956909
references.citation: Mov Disord. 2011 Jul;26(8):1552-5
references.pmid: 21538524
references.citation: Pharmacol Biochem Behav. 2012 Jan;100(3):607-15
references.pmid: 21978941
references.citation: Nat Rev Neurosci. 2001 Aug;2(8):577-88
references.pmid: 11484001
references.citation: Neurology. 2012 Jul 10;79(2):163-9
references.pmid: 22744665
references.citation: Arch Neurol. 2003 Mar;60(3):337-41
references.pmid: 12633144
references.citation: Mov Disord. 2013 Feb;28(2):131-44
references.pmid: 23225267
references.citation: Mov Disord. 1999 Sep;14(5):744-53
references.pmid: 10495035
references.citation: Neurology. 2011 Apr 5;76(14):1256-62
references.pmid: 21464430
references.citation: Trends Neurosci. 2006 Nov;29(11):647-54
references.pmid: 17030429
references.citation: Neurology. 2010 Oct 5;75(14):1263-9
references.pmid: 20810998